Abstract
Context: Irisin is an exercise-induced novel myokine that drives brown-fat-like conversion of white adipose tissue and has been suggested to be a promising target for the treatment of obesity-related metabolic disorders. Objective: To assess the association of circulating irisin concentrations with brown adipose tissue (BAT) and/or sarcopenia in humans. SettingandDesign: Weexaminedirisin levels in40BAT-positiveand40BAT-negativewomendetected by 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET). In a separate study, we also examined 401 subjects with or without sarcopenia defined by skeletal muscle mass index (SMMI) and appendicular skeletal muscle (ASM)/height2 using dual-energy x-ray absorptiometry. Results:Among6877 consecutive 18FDG-PET scans in 4736 subjects, 146 subjects (3.1%) had positive BAT scans. The BAT-detectable group and the matched BAT-undetectable group did not differ in circulating irisin levels measured using two different ELISA kits (P=.747 and P=.160, respectively). Serum irisin levels were not different between individuals with sarcopenia and those without sarcopenia using either kit (P = .305 and P = .569, respectively). Also, serum irisin levels were not different between groups defined by ASM/height2 using either kit (P = .352 and P = .134, respectively). Although visceral fat area and skeletal muscle mass showed significant difference according to tertiles of SMMI levels, irisin concentrations did not differ. Conclusions: Circulating irisin levels were not different in individuals with detectable BAT or those with sarcopenia compared with control subjects and were not correlated with SMMI.
| Original language | English |
|---|---|
| Pages (from-to) | 2778-2785 |
| Number of pages | 8 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 99 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Clinical Biochemistry
- Endocrinology
- Biochemistry, medical
- Endocrinology, Diabetes and Metabolism
Cite this
Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans. / Choi, Hae Yoon; Kim, Sungeun; Park, Ji Woo; Lee, Nam Seok; Hwang, Soon Young; Huh, Joo Young; Hong, Ho Cheol; Yoo, Hye-Jin; Baik, Sei-Hyun; Youn, Byung Soo; Mantzoros, Christos S.; Choi, Kyung Mook.
In: Journal of Clinical Endocrinology and Metabolism, Vol. 99, No. 8, 01.01.2014, p. 2778-2785.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans
AU - Choi, Hae Yoon
AU - Kim, Sungeun
AU - Park, Ji Woo
AU - Lee, Nam Seok
AU - Hwang, Soon Young
AU - Huh, Joo Young
AU - Hong, Ho Cheol
AU - Yoo, Hye-Jin
AU - Baik, Sei-Hyun
AU - Youn, Byung Soo
AU - Mantzoros, Christos S.
AU - Choi, Kyung Mook
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Context: Irisin is an exercise-induced novel myokine that drives brown-fat-like conversion of white adipose tissue and has been suggested to be a promising target for the treatment of obesity-related metabolic disorders. Objective: To assess the association of circulating irisin concentrations with brown adipose tissue (BAT) and/or sarcopenia in humans. SettingandDesign: Weexaminedirisin levels in40BAT-positiveand40BAT-negativewomendetected by 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET). In a separate study, we also examined 401 subjects with or without sarcopenia defined by skeletal muscle mass index (SMMI) and appendicular skeletal muscle (ASM)/height2 using dual-energy x-ray absorptiometry. Results:Among6877 consecutive 18FDG-PET scans in 4736 subjects, 146 subjects (3.1%) had positive BAT scans. The BAT-detectable group and the matched BAT-undetectable group did not differ in circulating irisin levels measured using two different ELISA kits (P=.747 and P=.160, respectively). Serum irisin levels were not different between individuals with sarcopenia and those without sarcopenia using either kit (P = .305 and P = .569, respectively). Also, serum irisin levels were not different between groups defined by ASM/height2 using either kit (P = .352 and P = .134, respectively). Although visceral fat area and skeletal muscle mass showed significant difference according to tertiles of SMMI levels, irisin concentrations did not differ. Conclusions: Circulating irisin levels were not different in individuals with detectable BAT or those with sarcopenia compared with control subjects and were not correlated with SMMI.
AB - Context: Irisin is an exercise-induced novel myokine that drives brown-fat-like conversion of white adipose tissue and has been suggested to be a promising target for the treatment of obesity-related metabolic disorders. Objective: To assess the association of circulating irisin concentrations with brown adipose tissue (BAT) and/or sarcopenia in humans. SettingandDesign: Weexaminedirisin levels in40BAT-positiveand40BAT-negativewomendetected by 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET). In a separate study, we also examined 401 subjects with or without sarcopenia defined by skeletal muscle mass index (SMMI) and appendicular skeletal muscle (ASM)/height2 using dual-energy x-ray absorptiometry. Results:Among6877 consecutive 18FDG-PET scans in 4736 subjects, 146 subjects (3.1%) had positive BAT scans. The BAT-detectable group and the matched BAT-undetectable group did not differ in circulating irisin levels measured using two different ELISA kits (P=.747 and P=.160, respectively). Serum irisin levels were not different between individuals with sarcopenia and those without sarcopenia using either kit (P = .305 and P = .569, respectively). Also, serum irisin levels were not different between groups defined by ASM/height2 using either kit (P = .352 and P = .134, respectively). Although visceral fat area and skeletal muscle mass showed significant difference according to tertiles of SMMI levels, irisin concentrations did not differ. Conclusions: Circulating irisin levels were not different in individuals with detectable BAT or those with sarcopenia compared with control subjects and were not correlated with SMMI.
UR - http://www.scopus.com/inward/record.url?scp=84905836995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905836995&partnerID=8YFLogxK
U2 - 10.1210/jc.2014-1195
DO - 10.1210/jc.2014-1195
M3 - Article
VL - 99
SP - 2778
EP - 2785
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 8
ER -